Antihypertensive efficacy of amlodipine in children with chronic kidney diseases
In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney d...
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 2001-06, Vol.15 (6), p.387-391 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 391 |
|---|---|
| container_issue | 6 |
| container_start_page | 387 |
| container_title | Journal of human hypertension |
| container_volume | 15 |
| creator | VON VIGIER, R. O FRANSCINI, L. M. D BIANDA, N. D. F PFISTER, R AEBISCHER, C. Casaulta BIANCHETTI, M. G |
| description | In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney diseases. The patients were given amlodipine for 16 weeks as part of their antihypertensive treatment. Before amlodipine arterial pressure was 150 (142-163)/90 (84-95) mm Hg (median and interquartile range). Six patients withdrew from amlodipine because of oedema, flushing or headache. In the remaining patients amlodipine 7.7 (6.9-9.4) mg/m(2) body surface area once a day significantly decreased arterial pressure by 17 (13-22)/10 (7-13) mm Hg. The efficacy of amlodipine was more pronounced in girls than in boys. No changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients circulating potassium, sodium or creatinine changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial. In conclusion the present experience in paediatric outpatients with chronic kidney diseases supports the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day. |
| doi_str_mv | 10.1038/sj.jhh.1001203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2640630107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2640630107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-9e3784f3d59db6911645a201e088b86e19d280c8082624e6898794ad434003503</originalsourceid><addsrcrecordid>eNp10EtLxDAQB_Agiq6Pq0cpiseuk0fT5CjiCwQ96LlkkylN3U3XpKvstzdiwZOnTJjfzMCfkFMKcwpcXaV-3nddroEy4DtkRkUty6pi9S6Zga6g1EzAATlMqc8mN9U-OaBUcM0pn5GX6zD6brvGOGJI_hMLbFtvjd0WQ1uY1XJwfu0DFj4UtvNLFzEUX37s8i8Owdvi3buA28L5hCZhOiZ7rVkmPJneI_J2d_t681A-Pd8_3lw_lVZQOZYaea1Ey12l3UJqSqWoDAOKoNRCSaTaMQVWgWKSCZRKq1oL4wQXALwCfkQufveu4_CxwTQ2_bCJIZ9smBQgOVCoszr_V1Gta0EZz2j-i2wcUorYNuvoVyZuGwrNT8pN6puccjOlnAfOpq2bxQrdH59izeByAiZZs2yjCdanPyeyUfn0N5Q5g0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219974123</pqid></control><display><type>article</type><title>Antihypertensive efficacy of amlodipine in children with chronic kidney diseases</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>VON VIGIER, R. O ; FRANSCINI, L. M. D ; BIANDA, N. D. F ; PFISTER, R ; AEBISCHER, C. Casaulta ; BIANCHETTI, M. G</creator><creatorcontrib>VON VIGIER, R. O ; FRANSCINI, L. M. D ; BIANDA, N. D. F ; PFISTER, R ; AEBISCHER, C. Casaulta ; BIANCHETTI, M. G</creatorcontrib><description>In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney diseases. The patients were given amlodipine for 16 weeks as part of their antihypertensive treatment. Before amlodipine arterial pressure was 150 (142-163)/90 (84-95) mm Hg (median and interquartile range). Six patients withdrew from amlodipine because of oedema, flushing or headache. In the remaining patients amlodipine 7.7 (6.9-9.4) mg/m(2) body surface area once a day significantly decreased arterial pressure by 17 (13-22)/10 (7-13) mm Hg. The efficacy of amlodipine was more pronounced in girls than in boys. No changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients circulating potassium, sodium or creatinine changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial. In conclusion the present experience in paediatric outpatients with chronic kidney diseases supports the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/sj.jhh.1001203</identifier><identifier>PMID: 11439313</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing</publisher><subject>Adolescent ; Adult ; Age Factors ; Amlodipine - administration & dosage ; Amlodipine - adverse effects ; Amlodipine - pharmacokinetics ; Antihypertensive agents ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Antihypertensives ; Biological and medical sciences ; Blood pressure ; Blood Pressure - drug effects ; Body weight ; Calcium antagonists ; Cardiovascular system ; Child ; Child Welfare ; Child, Preschool ; Chronic Disease ; Creatinine ; Cyclosporins ; Diuretics ; Edema ; European Continental Ancestry Group ; Female ; Heart rate ; Heart Rate - drug effects ; Hemoglobin ; Humans ; Hypertension, Renal - drug therapy ; Infant ; Kidney diseases ; Kidney Diseases - drug therapy ; Kidney Glomerulus ; Linear Models ; Male ; Medical sciences ; Patients ; Pediatrics ; Pharmacology. Drug treatments ; Potassium ; Prospective Studies ; Surveys and Questionnaires ; Therapeutic Equivalency ; Treatment Outcome</subject><ispartof>Journal of human hypertension, 2001-06, Vol.15 (6), p.387-391</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jun 2001</rights><rights>Macmillan Publishers Limited 2001.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-9e3784f3d59db6911645a201e088b86e19d280c8082624e6898794ad434003503</citedby><cites>FETCH-LOGICAL-c416t-9e3784f3d59db6911645a201e088b86e19d280c8082624e6898794ad434003503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14133812$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11439313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VON VIGIER, R. O</creatorcontrib><creatorcontrib>FRANSCINI, L. M. D</creatorcontrib><creatorcontrib>BIANDA, N. D. F</creatorcontrib><creatorcontrib>PFISTER, R</creatorcontrib><creatorcontrib>AEBISCHER, C. Casaulta</creatorcontrib><creatorcontrib>BIANCHETTI, M. G</creatorcontrib><title>Antihypertensive efficacy of amlodipine in children with chronic kidney diseases</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><description>In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney diseases. The patients were given amlodipine for 16 weeks as part of their antihypertensive treatment. Before amlodipine arterial pressure was 150 (142-163)/90 (84-95) mm Hg (median and interquartile range). Six patients withdrew from amlodipine because of oedema, flushing or headache. In the remaining patients amlodipine 7.7 (6.9-9.4) mg/m(2) body surface area once a day significantly decreased arterial pressure by 17 (13-22)/10 (7-13) mm Hg. The efficacy of amlodipine was more pronounced in girls than in boys. No changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients circulating potassium, sodium or creatinine changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial. In conclusion the present experience in paediatric outpatients with chronic kidney diseases supports the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Amlodipine - administration & dosage</subject><subject>Amlodipine - adverse effects</subject><subject>Amlodipine - pharmacokinetics</subject><subject>Antihypertensive agents</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Antihypertensives</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Body weight</subject><subject>Calcium antagonists</subject><subject>Cardiovascular system</subject><subject>Child</subject><subject>Child Welfare</subject><subject>Child, Preschool</subject><subject>Chronic Disease</subject><subject>Creatinine</subject><subject>Cyclosporins</subject><subject>Diuretics</subject><subject>Edema</subject><subject>European Continental Ancestry Group</subject><subject>Female</subject><subject>Heart rate</subject><subject>Heart Rate - drug effects</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hypertension, Renal - drug therapy</subject><subject>Infant</subject><subject>Kidney diseases</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Glomerulus</subject><subject>Linear Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium</subject><subject>Prospective Studies</subject><subject>Surveys and Questionnaires</subject><subject>Therapeutic Equivalency</subject><subject>Treatment Outcome</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp10EtLxDAQB_Agiq6Pq0cpiseuk0fT5CjiCwQ96LlkkylN3U3XpKvstzdiwZOnTJjfzMCfkFMKcwpcXaV-3nddroEy4DtkRkUty6pi9S6Zga6g1EzAATlMqc8mN9U-OaBUcM0pn5GX6zD6brvGOGJI_hMLbFtvjd0WQ1uY1XJwfu0DFj4UtvNLFzEUX37s8i8Owdvi3buA28L5hCZhOiZ7rVkmPJneI_J2d_t681A-Pd8_3lw_lVZQOZYaea1Ey12l3UJqSqWoDAOKoNRCSaTaMQVWgWKSCZRKq1oL4wQXALwCfkQufveu4_CxwTQ2_bCJIZ9smBQgOVCoszr_V1Gta0EZz2j-i2wcUorYNuvoVyZuGwrNT8pN6puccjOlnAfOpq2bxQrdH59izeByAiZZs2yjCdanPyeyUfn0N5Q5g0c</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>VON VIGIER, R. O</creator><creator>FRANSCINI, L. M. D</creator><creator>BIANDA, N. D. F</creator><creator>PFISTER, R</creator><creator>AEBISCHER, C. Casaulta</creator><creator>BIANCHETTI, M. G</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20010601</creationdate><title>Antihypertensive efficacy of amlodipine in children with chronic kidney diseases</title><author>VON VIGIER, R. O ; FRANSCINI, L. M. D ; BIANDA, N. D. F ; PFISTER, R ; AEBISCHER, C. Casaulta ; BIANCHETTI, M. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-9e3784f3d59db6911645a201e088b86e19d280c8082624e6898794ad434003503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Amlodipine - administration & dosage</topic><topic>Amlodipine - adverse effects</topic><topic>Amlodipine - pharmacokinetics</topic><topic>Antihypertensive agents</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Antihypertensives</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Body weight</topic><topic>Calcium antagonists</topic><topic>Cardiovascular system</topic><topic>Child</topic><topic>Child Welfare</topic><topic>Child, Preschool</topic><topic>Chronic Disease</topic><topic>Creatinine</topic><topic>Cyclosporins</topic><topic>Diuretics</topic><topic>Edema</topic><topic>European Continental Ancestry Group</topic><topic>Female</topic><topic>Heart rate</topic><topic>Heart Rate - drug effects</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hypertension, Renal - drug therapy</topic><topic>Infant</topic><topic>Kidney diseases</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Glomerulus</topic><topic>Linear Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium</topic><topic>Prospective Studies</topic><topic>Surveys and Questionnaires</topic><topic>Therapeutic Equivalency</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VON VIGIER, R. O</creatorcontrib><creatorcontrib>FRANSCINI, L. M. D</creatorcontrib><creatorcontrib>BIANDA, N. D. F</creatorcontrib><creatorcontrib>PFISTER, R</creatorcontrib><creatorcontrib>AEBISCHER, C. Casaulta</creatorcontrib><creatorcontrib>BIANCHETTI, M. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VON VIGIER, R. O</au><au>FRANSCINI, L. M. D</au><au>BIANDA, N. D. F</au><au>PFISTER, R</au><au>AEBISCHER, C. Casaulta</au><au>BIANCHETTI, M. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antihypertensive efficacy of amlodipine in children with chronic kidney diseases</atitle><jtitle>Journal of human hypertension</jtitle><addtitle>J Hum Hypertens</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>15</volume><issue>6</issue><spage>387</spage><epage>391</epage><pages>387-391</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney diseases. The patients were given amlodipine for 16 weeks as part of their antihypertensive treatment. Before amlodipine arterial pressure was 150 (142-163)/90 (84-95) mm Hg (median and interquartile range). Six patients withdrew from amlodipine because of oedema, flushing or headache. In the remaining patients amlodipine 7.7 (6.9-9.4) mg/m(2) body surface area once a day significantly decreased arterial pressure by 17 (13-22)/10 (7-13) mm Hg. The efficacy of amlodipine was more pronounced in girls than in boys. No changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients circulating potassium, sodium or creatinine changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial. In conclusion the present experience in paediatric outpatients with chronic kidney diseases supports the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day.</abstract><cop>Basingstoke</cop><pub>Nature Publishing</pub><pmid>11439313</pmid><doi>10.1038/sj.jhh.1001203</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 2001-06, Vol.15 (6), p.387-391 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_journals_2640630107 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent Adult Age Factors Amlodipine - administration & dosage Amlodipine - adverse effects Amlodipine - pharmacokinetics Antihypertensive agents Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Antihypertensives Biological and medical sciences Blood pressure Blood Pressure - drug effects Body weight Calcium antagonists Cardiovascular system Child Child Welfare Child, Preschool Chronic Disease Creatinine Cyclosporins Diuretics Edema European Continental Ancestry Group Female Heart rate Heart Rate - drug effects Hemoglobin Humans Hypertension, Renal - drug therapy Infant Kidney diseases Kidney Diseases - drug therapy Kidney Glomerulus Linear Models Male Medical sciences Patients Pediatrics Pharmacology. Drug treatments Potassium Prospective Studies Surveys and Questionnaires Therapeutic Equivalency Treatment Outcome |
| title | Antihypertensive efficacy of amlodipine in children with chronic kidney diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T04%3A38%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antihypertensive%20efficacy%20of%20amlodipine%20in%20children%20with%20chronic%20kidney%20diseases&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=VON%20VIGIER,%20R.%20O&rft.date=2001-06-01&rft.volume=15&rft.issue=6&rft.spage=387&rft.epage=391&rft.pages=387-391&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/sj.jhh.1001203&rft_dat=%3Cproquest_cross%3E2640630107%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219974123&rft_id=info:pmid/11439313&rfr_iscdi=true |